“Concomitant Eruptive Squamous Atypia and Bullous Drug Eruption Associated with Pembrolizumab” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), pp. 2006–2010. doi:10.25251/skin.8.6.17.